Frequently Asked Questions
The market is segmented based on Segmentation, By Product Type (Value-Added Branded Generics, Trade Named Generics), Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-Inflammatory, Others), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptic, Others), Consumption Type (Oral, Parenteral, Topical, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) – Industry Trends and Forecast to 2031.
.
The Global Branded Generics Market size was valued at USD 341.13 USD Billion in 2023.
The Global Branded Generics Market is projected to grow at a CAGR of 8.03% during the forecast period of 2024 to 2031.
The major players operating in the market include , Abbott , Allergan , Merck & Co. , Pfizer , GlaxoSmithKline plc , F. Hoffmann,La Roche , Mylan N.V. , Teva Pharmaceutical Industries , Sanofi , Novartis AG , Bayer AG , Sun Pharmaceutical Industries , Aurobindo Pharma , Lupin , AstraZeneca , Johnson & Johnson Private Limited , Zydus Cadila , Dr. Reddy's Laboratories , Apotex .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
